Our History
As the pioneers in vacuum-assisted breast biopsy, Mammotome is proud to celebrate 30 years of innovation.
30 Years of Breast Care Innovation
1995
It all began with the Mammotome® Breast Biopsy System. This technology transformed breast cancer intervention from open surgical biopsy to minimally invasive procedures. Originally known as Biopsys, this system provided an accurate diagnosis, while greatly improving the overall patient experience.
1997
Ethicon Endo-Surgery (EES), part of the Johnson & Johnson Family of Companies, acquired Biopsys. EES continued product development on the Mammotome® biopsy system, expanding the Mammotome brand into the worldwide market leader.
1999
The Mammotome® HH Breast Biopsy System for ultrasound-guided procedures was introduced to the market, a true milestone in the diagnosis of breast lesions.
2001
The Mammotome® ST Breast Biopsy System launched, providing an enhanced biopsy system specifically designed for stereotactic procedures. Mammotome also introduced the MicroMARK II breast biopsy tissue marker.
2004
The Mammotome® system expanded to include Mammotome® EX for ultrasound-guided biopsy procedures. Mammotome also introduced the MammoMARK® line of biopsy site identifiers, designed to enhance performance accuracy in biopsy site marking.
2006
The Mammotome® Breast Biopsy System expanded to include MR for magnetic resonance imaging-guided procedures.
2010
Devicor Medical Products, Inc. acquired the Mammotome breast care business from Ethicon-Endo Surgery.
2011
Devicor Medical Products, Inc. acquired the Neoprobe® Gamma Detection System portfolio of products from Neoprobe Corporation, creating a newly combined breast biopsy and breast surgery portfolio.
2012
In 2012, the Mammotome® Elite Tetherless Vacuum-Assisted Biopsy System launched. The MammoSTAR® Biopsy Site Markers were added to the Mammotome® Markers portfolio, providing an all-natural marking alternative.
2013
Mammotome unveiled the Mammotome Revolve™ Dual Vacuum-Assisted Breast Biopsy System for stereotactic procedures, truly redefining biopsy procedural efficiency without compromising tissue quality.
2014
In 2014, Mammotome greatly expanded its product portfolio. First the launch of the Mammotome Revolve™ U/S Dual Vacuum-Assisted Breast Biopsy System for ultrasound procedures. Two exciting acquisitions including the HydroMARK™ Breast Biopsy Site Marker portfolio and the MammoTest® stereotactic biopsy table. Finally, a distribution agreement was signed for the Faxitron CoreVision in-room specimen radiograph system.
2014
Devicor Medical Products, Inc. was acquired by Leica Biosystems, bringing Mammotome under the Danaher Corporation umbrella.
2018
Mammotome enters into a distribution agreement with KUB Technologies, Inc. to distribute their line of specimen radiography systems, replacing the Faxitron CoreVision with the Mammotome Confirm™ Core Specimen Radiography System
2019
Mammotome began distribution of the Tru-Core™ II Automatic Biopsy Instrument.
2020
Mammotome launched the HydroMARKTM flexible applicators designed to make the clinician’s user experience easier and more intuitive. Mammotome celebrated 25 years of innovation in breast cancer diagnostics. To date, more than 11 million women worldwide have had a successful procedure using a Mammotome breast care solution.1
2023
The Mammotome Revolve™ EX Dual Vacuum-Assisted Breast Biopsy System for lesion excision was launched. It is the first VAB system designed specifically for lesion excision with an expanded flexible collection system to store multiple lesion areas.
2025
Mammotome unveiled enhancements to the Mammotome Revolve™ system to optimize efficiency and ease of use for clinicians.2 Mammotome and Sirius Medical entered into an exclusive distribution agreement of the Pintuition® System for the United States, Germany, Italy and Poland. This partnership reinforces both companies’ dedication to driving progress in breast cancer treatment by providing state-of-the-art tools that facilitate optimal care.
1. Based on internal sales data.
2. System refinements include simple and intuitive user interface, upgraded cart with tray that enables additional workspace with minimal footprint, and increased efficiency and ease of use for clinicians and staff.
Products may not be approved or available in your region. Please check with your local Mammotome representative.
Some products are no longer in production or distributed by Mammotome.
Mammotome is proud to be an authorized distributor of Sirius Pintuition®.